Abstract

Objective:

Despite a decline in cigarette use, the dual use of cigarettes and electronic vaping products (EVPs) is a concerning pattern of nicotine consumption in the United States. Anxiety, a risk factor for tobacco use, may contribute to dual-use patterns; however, the association between daily anxiety symptoms and dual use of cigarettes and EVPs is not known. This study investigated associations between daily anxiety symptoms and dual cigarette and EVP use overall and by sex, race, and ethnicity.

Method:

Data are from the 2020–2022 National Health Interview Survey (n = 83,544). Multinomial logistic regression models, adjusted for sociodemographic factors, tobacco use, mental health services, and medication characteristics, examined the relationship between daily anxiety and current exclusive/dual cigarette and EVP use. Stratified analyses explored effect modification by sex, race, and ethnicity. Results:

Among the sample, 13.0% reported daily anxiety symptoms, and 1.3% reported dual cigarette and EVP use. Daily anxiety was associated with increased odds of exclusive cigarette (odds ratio [OR] = 1.54, 95% CI [1.42, 1.68]), exclusive EVP (OR = 1.44, 95% CI [1.23, 1.68]), and dual use (OR = 2.16, 95% CI [1.77, 2.63]). Stratified analyses showed significant associations between dual use and daily anxiety among Hispanic, non-Hispanic White, non-Hispanic Black, and non-Hispanic Asian adults. Of note, Hispanic males and females, non-Hispanic White males and females, Black females, non-Hispanic Asian males, and females of another race/ethnicity had higher odds of dual use, whereas Asian females had lower odds. Conclusions:

This study highlights heterogeneous relationships between daily anxiety and dual cigarette and EVP use at the intersection of sex, race, and ethnicity. Tailored interventions addressing persistent mental health symptoms are crucial for reducing tobacco use and associated disparities.

Document Type

Article

Publication Date

2025

Digital Object Identifier (DOI)

https://doi.org/10.15288/jsad.24-00310

Funding Information

This research was supported, in part, by funding from the National Heart, Lung, and Blood Institute and the Center for Tobacco Products (U54HL120163), the National Institute on Drug Abuse (R25DA054015), and the National Cancer Institute (R01CA251478-04S1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. Food and Drug Administration, or the American Heart Association. The funding sponsors had no role in study design; data collection, analyses, or interpretation; manuscript preparation; or the decision to publish the results.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.